COVID-19 Outbreak-Global mRNA Vaccines & Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

For a long time, messenger RNA (mRNA) was thought to be a poor choice for a therapeutic agent given its relatively short half-life and its immunogenicity. But mRNA is rather versatile and offers a range of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
The mRNA Vaccines & Therapeutics market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the mRNA Vaccines & Therapeutics industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

The mRNA Vaccines & Therapeutics market can be split based on product types, major applications, and important countries as follows:

Key players in the global mRNA Vaccines & Therapeutics market covered in Chapter 12:
Ethris
AstraZeneca
Precision NanoSystems
Roche Custom Biotech
ETheRNA immunotherapies
CureVac
GlaxoSmithKline Vaccines
RaNa Therapeutics
PhaseRx
In-Cell-Art
Boehringer Ingelheim
Argos Therapeutics
Moderna Therapeutics
Janssen
Novartis
Bayer
BioNTech
MaxCyte
Intellia Therapeutics
Kernal Biologics
CRISPR Therapeutics

In Chapter 4 and 14.1, on the basis of types, the mRNA Vaccines & Therapeutics market from 2015 to 2025 is primarily split into:
Standardization Of Cancer Treatment MRNA Vaccine
Individualized Cancer Treatment MRNA Vaccine
Infectious Disease Treatment MRNA Vaccine
Infection Prevention MRNA Vaccine

In Chapter 5 and 14.2, on the basis of applications, the mRNA Vaccines & Therapeutics market from 2015 to 2025 covers:
Hospital
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:

Historical Years:

2015-2019

Base Year:

2019

Estimated Year:

2020

Forecast Period:

2020-2025